Neoadjuvant Pertuzumab (P) and Trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC) (Abstract S5-1; Gianni L et al.)